Individuals With MCI Develop Clinical AD At A Much Higher Rate Than Normal Elderly

3/16/01


Click here to start


Table of Contents

PPT Slide

Individuals With MCI Develop Clinical AD At A Much Higher Rate Than Normal Elderly

Memory Testing Increases the Prediction Accuracy of Future AD Over Clinical Evaluation Alone

Prevention of AD is Highly Desirable but Prevention Trials with Clinically Normal Individuals are Necessarily Large and Expensive

Far Fewer MCI Subjects Than Normals Are Needed to Demonstrate a 33% Reduction in Conversion Rate to AD

Advantages of MCI/AD Prevention Trials Over Primary Prevention Trials

MCI Trial with Vitamin E and Donepezil

Subject Selection

MCI Trial Endpoints

MCI Trial Participants At Baseline Have Memory Deficits But Are Much Less Impaired than Patients in Standard AD Trials

MCI Study Participants Have Only Subtle Impairment in Function Compared to Mild AD Patients

Hippocampal Volume Correlates with Baseline Memory Performance

Rate of Conversion to AD in MCI Trial at 1 Year Approximates Predicted Rate

MCI Participants Progress at a Slower Annual Rate Than Patients in Standard AD Trials

MCI Trial Participants Generally Decline Slowly While Converters to AD Show More Rapid Decline over 1 Year

Conclusions

Conclusions

Clinical Value of MCI Diagnosis

Author: Michael